Investment Rating - The industry rating is "Recommended" [3] Core Insights - The report emphasizes the need for high-quality development in the pig farming industry, focusing on improving efficiency and quality. It highlights the importance of capacity control and the encouragement of large enterprises to collaborate with smaller farms to share industry benefits [2][12] - In the planting industry, the report discusses the promotion of new varieties and technologies to enhance crop yields, particularly in the context of food security. It predicts a continued acceleration in the commercialization of genetically modified crops [1][11] Summary by Sections Planting Industry - The Ministry of Agriculture and Rural Affairs is working on a directory for superior crop varieties by 2025, focusing on enhancing yields and meeting current production needs [1][11] - The report identifies potential beneficiaries in the planting sector, including Beidahuang and Su-Kun Agricultural Development, and recommends companies with strong advantages in seed development such as Longping High-Tech and Denge Seed Industry [1][11] Pig Farming - The average price of external three-way cross pigs is 14.29 CNY/kg, showing a week-on-week decrease of 1.20%. The overall supply exceeds demand, leading to a forecast of continued price declines [2][12] - The report notes a decrease in the number of breeding sows, with a total of 40.43 million as of June 2025, down by 370,000 from the previous year [2][12] - Recommended companies in the pig farming sector include Dekang Agriculture, Jingji Zhino, Muyuan Foods, and Wens Foodstuff [2][12] Feed and Animal Health - The average price of pig feed is 2.72 CNY/kg, with no change from the previous week. The report also provides insights into the prices of various feed types for poultry and livestock [50][52]

截至2025年7月25日收盘，中牧股份（600195）报收于7.88元，较上周的7.89元下跌0.13%。本周，中牧 股份7月25日盘中最高价报8.03元。7月24日盘中最低价报7.75元。中牧股份当前最新总市值80.47亿元， 在动物保健板块市值排名4/11，在两市A股市值排名2113/5148。 本周关注点 公司公告汇总: 中牧股份收到首笔搬迁补偿款人民币贰仟万元整 公司公告汇总 中牧实业股份有限公司（股票代码：600195）于2024年10月29日召开第八届董事会2024年第二十一次临 时会议，审议通过了关于公司拟签订《成都市国有土地上房屋搬迁补偿协议》的议案，同意公司与成都 成华棚户区惠民改造建设有限责任公司签订关于成都市成华区蜀陵路59号的搬迁补偿协议，并授权公司 管理层操作具体事宜。2024年11月13日，双方正式签订了该协议，搬迁补偿款将分阶段支付。2025年7 月23日，公司收到首笔搬迁补偿款人民币贰仟万元整（¥20,000,000.00）。公司将根据《企业会计准 则》对上述款项进行相应会计处理，具体影响以会计师事务所年度审计结果为准。本次搬迁事项符合相 关法律法规和政策文件的规定，涉及的土地 ...

Group 1 - The horse racing concept sector declined by 2.40%, ranking among the top declines in concept sectors, with *ST Zhengping hitting the limit down, and companies like Luoniushan, Hainan Rubber, and Zhujiang Piano also experiencing significant declines [1] - Among the horse racing concept stocks, only two saw price increases, with Zhongmu Co. rising by 0.25% and Xinhua Dou by 0.15% [1] - The horse racing concept sector experienced a net outflow of 138 million yuan from main funds today, with Luoniushan leading the outflow at 94.32 million yuan [2] Group 2 - The top gainers in concept sectors included Sora concept (2.98%), lithography machines (2.79%), and multimodal AI (2.30%), while the Hainan Free Trade Zone and horse racing concept were among the largest decliners [2] - The main fund outflow rankings for the horse racing concept included Luoniushan (-5.54%), *ST Zhengping (-4.88%), and Hainan Rubber (-5.45%) [2] - The trading turnover rate for Luoniushan was 10.64%, while *ST Zhengping had a turnover rate of 4.64% [2]

股票代码：600195 股票简称：中牧股份 编号：临 2025-021 中牧实业股份有限公司关于收到搬迁补偿款 的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 7 月 23 日 ， 公 司 收 到 搬 迁 补 偿 款 人 民 币 贰 仟 万 元 整 （¥20,000,000.00）。 公司将根据《企业会计准则》等相关规定，对上述搬迁补偿款进行相应的会 计处理，具体会计处理及其对相关财务数据的影响情况以会计师事务所年度审计 后的结果为准。 本次搬迁事项符合相关法律、法规及相关搬迁政策文件的相关规定，涉及搬 迁的土地房产不用于公司产品生产经营，本事项不会对公司的正常生产经营造成 不利影响。 三、其他说明 公司将密切关注本事项的进展情况，并按照相关规定，及时履行信息披露义 务。在协议履行过程中可能因国家政策等不可预见的或其它不可抗力因素，从而 影响协议的最终执行情况，敬请广大投资者谨慎投资，关注投资风险。 特此公告 一、情况概述 中牧实业股份有限公司（以下简称"中牧股份"或"公司"）于 2024 年 10 ...

Group 1 - The animal vaccine sector experienced a decline of 0.96%, ranking among the top losers in the concept sector, with companies like BioShares, Zhongmu, and Pulaike leading the declines [1][2] - Among the animal vaccine stocks, five companies saw price increases, with Luoniushan, Weilan Biology, and Dabeinong rising by 1.42%, 1.38%, and 0.73% respectively [1][2] - The animal vaccine sector faced a net outflow of 218 million yuan from main funds, with 12 stocks experiencing outflows, and six stocks seeing outflows exceeding 10 million yuan [2][3] Group 2 - The top net outflow stock was BioShares, with a net outflow of 128 million yuan, followed by Xianfeng Holdings, Jinhai Biological, and Zhongmu, with net outflows of 41.99 million yuan, 26.07 million yuan, and 25.32 million yuan respectively [2][3] - Conversely, the stocks with the highest net inflow included Dabeinong, Luoniushan, and Weilan Biology, attracting net inflows of 34.95 million yuan, 23.76 million yuan, and 13.06 million yuan respectively [2][3] - The detailed outflow data for the animal vaccine sector shows significant declines in stock prices, with BioShares down by 5.56% and a turnover rate of 11.26% [2][3]

Group 1 - The avian influenza concept sector declined by 0.90%, ranking among the top declines in concept sectors, with leading declines from companies such as Zhijiang Biology, Biological Shares, and Zhongmu Shares [1][2] - Among the 10 stocks that increased in price, Weilan Biology, Lianhuan Pharmaceutical, and Wens Foodstuff were the top gainers, with increases of 1.38%, 0.66%, and 0.53% respectively [1][2] - The avian influenza concept sector experienced a net outflow of 383 million yuan from main funds, with 17 stocks seeing net outflows, and 8 stocks with outflows exceeding 10 million yuan [2][3] Group 2 - The stock with the highest net outflow was Biological Shares, with a net outflow of 128 million yuan, followed by Zhongsheng Pharmaceutical, Taiji Group, and Zhijiang Biology with net outflows of 93.42 million yuan, 35.18 million yuan, and 33.51 million yuan respectively [2][3] - The stocks with the highest net inflows included Wens Foodstuff, Weilan Biology, and Oriental Biology, with net inflows of 16.02 million yuan, 13.06 million yuan, and 7.22 million yuan respectively [2][3] - The avian influenza concept sector's outflow list included Biological Shares, Zhongsheng Pharmaceutical, Taiji Group, and Zhijiang Biology, with respective declines of 5.56%, 0.45%, 0.27%, and 7.07% [2][3]

Group 1 - Datang Power achieved a total on-grid electricity of approximately 123.99 billion kWh for the first half of 2025, a year-on-year increase of 1.30%, with wind and solar power generation increasing by 31.27% and 36.35% respectively [1] - North Self Technology signed an equipment procurement contract with a total amount of 164 million yuan [1] - Jinchuan Co. reported a net profit of 1.38 billion yuan for the first half of 2025, a year-on-year decrease of 8.45%, with operating revenue of 6.96 billion yuan, an increase of 5.55% [1][2] Group 2 - Microchip Biotech expects a revenue of 407 million yuan for the first half of 2025, a year-on-year increase of 35%, and a net profit of approximately 30.06 million yuan, a year-on-year increase of 173% [3] - Zongheng Co. anticipates a revenue of 135 million yuan for the first half of 2025, a year-on-year increase of 61.72%, with a net loss of 34.68 million yuan, reducing losses by 18.34 million yuan compared to the previous year [5] - Tuojing Technology expects a revenue of 1.21 billion to 1.26 billion yuan for the second quarter of 2025, a year-on-year increase of 52% to 58%, with a net profit of 238 million to 247 million yuan, a year-on-year increase of 101% to 108% [7] Group 3 - Star Power reported a net profit of 73.42 million yuan for the first half of 2025, a year-on-year decrease of 13.44%, with total revenue of 1.52 billion yuan, an increase of 13.70% [8] - Xiamen Tungsten reported a net profit of 972 million yuan for the first half of 2025, a year-on-year decrease of 4.41%, with operating revenue of 19.18 billion yuan, an increase of 11.75% [9] - Yikang Pharmaceutical's subsidiary received approval for clinical trials of YKYY029 injection for hypertension [11] Group 4 - Mould Technology received a project designation for luxury car exterior parts, with an expected total sales of 2.044 billion yuan over a five-year lifecycle [13] - Jinzhik Technology won multiple projects from the State Grid and Southern Power Grid, with a total bid amount of 133 million yuan [14] - Changjiang Media plans to use up to 700 million yuan of idle funds to purchase financial products [16] Group 5 - Ningbo Gaofa plans to invest up to 20 million USD to establish a production base in Morocco [20] - Xuantai Pharmaceutical's subsidiary received EU GMP certification for solid dosage production lines [22] - Changhua Group received a project designation for key metal structural components from a domestic new energy vehicle company, with an expected total sales of 235 million yuan over a four-year lifecycle [23]

股票代码：600195 股票简称：中牧股份 编号：临 2025-020 中牧实业股份有限公司 关于获得兽用生物制品临床试验批件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 疫苗产品从前期研发到上市销售的周期较长，且由于非洲猪瘟病毒免疫机制 的复杂性，本项目在临床试验客观上存在一定的风险，项目研究开发进度、技术 成果、后期产业化应用进程等尚存在一定的不确定性。根据我国《兽药管理条例》 和《兽药注册办法》的规定，兽用生物制品在获得临床试验批准后，尚需完成临 床试验并申报注册，经农业农村部审评、审批通过，获得新兽药证书、兽药产品 批准文号后，方可上市销售。 公司将密切关注后续进展并及时履行信息披露义务，敬请广大投资者理性投 资，注意风险。 特此公告 近日，中牧实业股份有限公司（以下简称"公司"）收到了农业农村部颁发 的非洲猪瘟亚单位疫苗临床试验批件（批件号：2025058），现将相关情况公告如 下： | 项目名称 | 非洲猪瘟亚单位疫苗临床试验 | | --- | --- | | 受理号 | 07020020250417- ...

Core Viewpoint - Zhongmu Co., Ltd. has received clinical trial approval for its African swine fever subunit vaccine from the Ministry of Agriculture and Rural Affairs, indicating progress in its vaccine development efforts [1] Group 1: Company Developments - The vaccine is aimed at preventing African swine fever virus infections, showcasing the company's commitment to addressing significant agricultural health issues [1] - The company has invested approximately 46.24 million yuan in research and development for the vaccine in collaboration with research institutions in 2023 [1] Group 2: Industry Context - The development of the vaccine highlights the long and uncertain process from research to market, emphasizing the challenges faced in the pharmaceutical and agricultural sectors [1] - Successful completion of clinical trials and subsequent regulatory approval are necessary steps before the vaccine can be marketed and sold [1]

Group 1 - The animal vaccine sector saw a rise of 2.91%, leading the concept sectors in growth, with 16 stocks increasing in value, including BioShares which hit the daily limit, and others like Kexing Pharmaceutical and Ruipu Bio rising by 7.15%, 5.65%, and 3.56% respectively [1] - The main inflow of funds into the animal vaccine sector was 281 million yuan, with 10 stocks receiving net inflows, and 6 stocks seeing inflows exceeding 10 million yuan, led by BioShares with a net inflow of 159 million yuan [1] - The top stocks by net inflow included Haizheng Pharmaceutical, Kexing Pharmaceutical, and Ruipu Bio, with net inflows of 53.91 million yuan, 52.39 million yuan, and 28.10 million yuan respectively [1] Group 2 - In terms of fund inflow ratios, BioShares, Kexing Pharmaceutical, and Luoniushan had the highest net inflow rates at 19.39%, 9.63%, and 8.85% respectively [2] - The animal vaccine concept fund inflow rankings showed BioShares with a daily increase of 10.04% and a turnover rate of 8.74%, while Haizheng Pharmaceutical and Kexing Pharmaceutical followed with increases of 2.71% and 7.15% respectively [2] - Other notable stocks included Ruipu Bio with a 5.65% increase and a turnover rate of 9.16%, and Luoniushan with a 3.49% increase and a turnover rate of 4.43% [2]